Effect of high sensitivity C-reactive protein on uric acid-related cardiometabolic risk in patients with coronary artery disease—a large multicenter prospective study

Although serum uric acid (SUA) is a risk factor for cardiometabolic outcome, but it remains unclear which patients with coronary artery disease (CAD) benefit the most from SUA lowering therapy (ULT). The association of SUA level, systemic inflammation and cardiometabolic risk is still unclear. The current study is aimed to examine whether SUA-associated cardiometabolic risk is modulated by systemic inflammation in CAD patients. A total of 16,598 CAD patients with baseline high-sensitivity C-Reactive Protein (hsCRP) and SUA available were included. Baseline and follow-up data were collected. The primary endpoint was major adverse cardiovascular and cerebrovascular events (MACCE), including death, myocardial infarction and stroke. In patients with hsCRP ≥ 2 mg/L, increasing quintiles of SUA were significantly associated with increased rates of 2-year MACCE (adjusted p < 0.001 for trend, p = 0.037 for interaction). Each unit increase in SUA levels was associated with a 11.3% increased risk of MACCE (adjusted p < 0.001, p = 0.002 for interaction). However, in patients with hsCRP < 2 mg/L, increasing quintiles of SUA were not associated with increased MACCE (adjusted p = 0.120). Elevated SUA levels are related to MACCE when hsCRP levels are 2 mg/L or more but not less than 2 mg/L. This finding suggests a potential benefit of combined ULT and anti-inflammation therapy in patients with hyperuricemia and greater systemic inflammation.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2024-11-26
DOI
https://doi.org/10.1038/s41598-024-75508-9
Citations
3
Primary Topic
Gout, Hyperuricemia, Uric Acid
Type
article
Field-Weighted Citation Impact
1.02

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effect of high sensitivity C-reactive protein on uric acid-related cardiometabolic risk in patients with coronary artery disease—a large multicenter prospective study

Jinqing Yuan, Weiting Cai, Qingsheng Wang, Xueyan Zhao et al.
3 citations
Scientific Reports
Gout, Hyperuricemia, Uric Acid
1.02
article

Effect of high sensitivity C-reactive protein on uric acid-related cardiometabolic risk in patients with coronary artery disease—a large multicenter prospective study

Jinqing Yuan, Weiting Cai, Qingsheng Wang, Xueyan Zhao, Xiaogang Guo, Ying Song, Yingqing Feng, Zhifang Wang, Xiaozeng Wang, Jianxin Li, Yaling Han, Zhenyu Liu, Zheng Zhang, Yi Yao, Jue Chen, Lei Song, Jingjing Xu, Yongzhen Zhang, Runlin Gao, Na Xu, Lin Jiang
article en
3 citations

Abstract

Although serum uric acid (SUA) is a risk factor for cardiometabolic outcome, but it remains unclear which patients with coronary artery disease (CAD) benefit the most from SUA lowering therapy (ULT). The association of SUA level, systemic inflammation and cardiometabolic risk is still unclear. The current study is aimed to examine whether SUA-associated cardiometabolic risk is modulated by systemic inflammation in CAD patients. A total of 16,598 CAD patients with baseline high-sensitivity C-Reactive Protein (hsCRP) and SUA available were included. Baseline and follow-up data were collected. The primary endpoint was major adverse cardiovascular and cerebrovascular events (MACCE), including death, myocardial infarction and stroke. In patients with hsCRP ≥ 2 mg/L, increasing quintiles of SUA were significantly associated with increased rates of 2-year MACCE (adjusted p < 0.001 for trend, p = 0.037 for interaction). Each unit increase in SUA levels was associated with a 11.3% increased risk of MACCE (adjusted p < 0.001, p = 0.002 for interaction). However, in patients with hsCRP < 2 mg/L, increasing quintiles of SUA were not associated with increased MACCE (adjusted p = 0.120). Elevated SUA levels are related to MACCE when hsCRP levels are 2 mg/L or more but not less than 2 mg/L. This finding suggests a potential benefit of combined ULT and anti-inflammation therapy in patients with hyperuricemia and greater systemic inflammation.

Scientific ReportsVol. 14(1)
Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking University (CN), Peking Union Medical College Hospital (CN), General Hospital of Shenyang Military Region (CN), Peking University Third Hospital (CN), Xinxiang Central Hospital (CN), Guangdong Provincial People's Hospital (CN), Fu Wai Hospital (CN), First Hospital of Lanzhou University (CN), First Hospital of Qinhuangdao (CN), First Affiliated Hospital Zhejiang University (CN), Lanzhou University (CN)
National Children's Research Centre, Chinese Academy of Medical Sciences, Fuwai Hospital, Chinese Academy of Medical Sciences
Good health and well-being
Openalex Percentile: Top 20%
Gout, Hyperuricemia, Uric Acid
1.02
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.